SG11202102491RA - Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof - Google Patents
Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereofInfo
- Publication number
- SG11202102491RA SG11202102491RA SG11202102491RA SG11202102491RA SG11202102491RA SG 11202102491R A SG11202102491R A SG 11202102491RA SG 11202102491R A SG11202102491R A SG 11202102491RA SG 11202102491R A SG11202102491R A SG 11202102491RA SG 11202102491R A SG11202102491R A SG 11202102491RA
- Authority
- SG
- Singapore
- Prior art keywords
- corticosteroid
- compositions
- methods
- crac inhibitor
- crac
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201841034710 | 2018-09-14 | ||
PCT/IB2019/057746 WO2020053834A1 (en) | 2018-09-14 | 2019-09-13 | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102491RA true SG11202102491RA (en) | 2021-04-29 |
Family
ID=68242781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102491RA SG11202102491RA (en) | 2018-09-14 | 2019-09-13 | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220040162A1 (ko) |
EP (1) | EP3849552A1 (ko) |
JP (1) | JP2022508468A (ko) |
KR (1) | KR20210062023A (ko) |
CN (1) | CN113557020A (ko) |
AU (1) | AU2019340601A1 (ko) |
BR (1) | BR112021004893A2 (ko) |
CA (1) | CA3112907A1 (ko) |
CL (1) | CL2021000616A1 (ko) |
CO (1) | CO2021004013A2 (ko) |
EA (1) | EA202190556A1 (ko) |
IL (1) | IL281342A (ko) |
MX (1) | MX2021003094A (ko) |
SG (1) | SG11202102491RA (ko) |
WO (1) | WO2020053834A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102587919B1 (ko) * | 2022-07-22 | 2023-10-11 | 주식회사 넥스트젠바이오사이언스 | 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
EP1143013A1 (en) | 2000-04-03 | 2001-10-10 | Warner-Lambert Company | Methods and compositions for screening Icrac modulators |
US7452675B2 (en) | 2002-01-25 | 2008-11-18 | The Queen's Medical Center | Methods of screening for TRPM4b modulators |
US7645588B2 (en) | 2003-03-04 | 2010-01-12 | Calcimedica, Inc. | Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use |
AU2004259347B2 (en) | 2003-07-23 | 2011-02-24 | Synta Pharmaceuticals, Corp. | Method for modulating calcium ion-release-activated calcium ion channels |
CA2580852A1 (en) | 2004-09-21 | 2006-03-30 | Synta Pharmaceutical Corp. | Compounds for inflammation and immune-related uses |
US20060141569A1 (en) | 2004-10-29 | 2006-06-29 | Matthew Hsu | Compositions and methods for the assay of G-protein coupled receptors and their ligands |
US8202999B2 (en) | 2005-01-07 | 2012-06-19 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
JP5307402B2 (ja) | 2005-01-25 | 2013-10-02 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫に関連する用途に用いる化合物 |
AU2006208043B2 (en) | 2005-01-25 | 2012-09-20 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
EP1984400B1 (en) | 2006-01-05 | 2012-11-28 | Immune Disease Institute, Inc. | Regulators of nfat |
JP2009524677A (ja) | 2006-01-25 | 2009-07-02 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 |
WO2007087429A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
US8623871B2 (en) | 2006-01-25 | 2014-01-07 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
EP1984337B1 (en) | 2006-01-25 | 2014-04-30 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
TW200806641A (en) | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted aromatic compounds for inflammation and immune-related uses |
ES2403368T3 (es) | 2006-01-31 | 2013-05-17 | Synta Pharmaceuticals Corporation | Compuestos de piridilfenilo para la inflamación y usos inmunorrelacionados |
US8119643B2 (en) | 2006-03-20 | 2012-02-21 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
AU2007230911A1 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
KR20090015056A (ko) | 2006-04-10 | 2009-02-11 | 더 퀸스 메디컬 센터 | Crac 조절자 및 약물 발견을 위한 그의 용도 |
US20080039392A1 (en) | 2006-05-26 | 2008-02-14 | The Regents Of The University Of California | CRAC channel and modulator screening methods |
US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
AU2007322116B2 (en) | 2006-11-13 | 2013-01-10 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
TW200901961A (en) | 2007-02-16 | 2009-01-16 | Synta Pharmaceuticals Corp | Substituted fused-ring compounds for inflammation and immune-related uses |
AU2008222602B2 (en) | 2007-03-05 | 2013-06-20 | The University Of Queensland | A target for breast cancer therapy and/or diagnosis |
WO2008118795A1 (en) | 2007-03-23 | 2008-10-02 | The Queen's Medical Center | Assays and methods for determining stim2 activity |
US8507269B2 (en) | 2007-05-24 | 2013-08-13 | Calcimedica, Inc. | Calcium channel proteins and uses thereof |
EP2182808A4 (en) | 2007-08-01 | 2011-09-21 | Synta Pharmaceuticals Corp | Pyridine compounds for inflammatory and immune uses |
TW200914440A (en) | 2007-08-01 | 2009-04-01 | Synta Pharmaceuticals Corp | Vinyl-aryl derivatives for inflammation and immune-related uses |
EP2184994B1 (en) | 2007-08-01 | 2013-09-25 | Synta Pharmaceuticals Corp. | Heterocycle-aryl compounds for inflammation and immune-related uses |
MX2010002712A (es) | 2007-09-10 | 2010-06-09 | Calcimedica Inc | Compuestos que modulan calcio intracelular. |
WO2009038775A1 (en) | 2007-09-20 | 2009-03-26 | Synta Pharmaceuticals Corp. | Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
US8389567B2 (en) | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CA2711644A1 (en) | 2008-01-07 | 2009-07-16 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
BRPI0917719A2 (pt) | 2008-08-27 | 2019-11-19 | Calcimedica Inc | compostos que modulam cálcio intracelular |
US20110257177A1 (en) | 2008-09-22 | 2011-10-20 | Calcimedica, Inc. | Benzylthiotetrazole inhibitors of store operated calcium release |
WO2010034011A2 (en) | 2008-09-22 | 2010-03-25 | Calcimedica, Inc. | Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release |
US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
AU2009300317A1 (en) | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
JP2012504603A (ja) | 2008-10-01 | 2012-02-23 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連の使用のための化合物 |
US20100130522A1 (en) | 2008-10-01 | 2010-05-27 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
WO2010048559A2 (en) | 2008-10-24 | 2010-04-29 | Calcimedica Inc. | Phenylpyrazole inhibitors of store operated calcium release |
EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
TW201103892A (en) | 2009-04-24 | 2011-02-01 | Glaxo Group Ltd | Compounds |
EP2477982A4 (en) | 2009-09-16 | 2013-04-03 | Calcimedica Inc | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM |
WO2011036130A1 (en) | 2009-09-24 | 2011-03-31 | F. Hoffmann-La Roche Ag | Indole derivatives as crac modulators |
US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
US20130079348A1 (en) | 2010-03-03 | 2013-03-28 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CA2797533A1 (en) | 2010-04-27 | 2011-11-10 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
AU2011248877B9 (en) | 2010-04-27 | 2015-11-05 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
AU2011293201B2 (en) | 2010-08-27 | 2015-11-05 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
EP2619200A4 (en) | 2010-09-22 | 2014-10-15 | Calcimedica Inc | COMPOUNDS AS MODULATORS OF INTRA CELLULAR CALCIUM |
KR20130106410A (ko) | 2010-10-30 | 2013-09-27 | 루핀 리미티드 | Crac 조절제인 옥사졸린과 이소옥사졸린 유도체 |
US20140221468A1 (en) | 2010-12-09 | 2014-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds that Modulate Store Operated Calcium Channels |
US20130143927A1 (en) | 2011-06-10 | 2013-06-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US20130090334A1 (en) | 2011-10-05 | 2013-04-11 | Hoffmann-La Roche Inc | Azabenzoxazine derivatives as crac modulators |
WO2013050270A1 (en) | 2011-10-05 | 2013-04-11 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as crac modulators |
US20140256771A1 (en) | 2011-10-19 | 2014-09-11 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9856240B2 (en) | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US20130109720A1 (en) | 2011-11-01 | 2013-05-02 | Hoffmann-La Roche Inc. | Indole inhibitors of crac |
US20130158066A1 (en) | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | 4-azaindole inhibitors of crac |
WO2013092444A1 (en) | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | Diazaindole inhibitors of crac |
WO2013092467A1 (en) | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | 7-azaindole inhibitors of crac |
IN2014MN02127A (ko) | 2012-05-02 | 2015-09-11 | Lupin Ltd | |
IN2014MN02126A (ko) | 2012-05-02 | 2015-09-11 | Lupin Ltd | |
WO2014043715A1 (en) | 2012-09-17 | 2014-03-20 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
EP2943197A1 (en) | 2013-01-10 | 2015-11-18 | Grünenthal GmbH | Pyrazolyl-based carboxamides ii as crac channel inhibitors |
AU2014204978A1 (en) | 2013-01-10 | 2015-08-20 | Grünenthal GmbH | Pyrazolyl-based carboxamides I as CRAC channel inhibitors |
EP3010586A1 (en) | 2013-06-21 | 2016-04-27 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
EP3013810A1 (en) | 2013-06-24 | 2016-05-04 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
EP2848615A1 (en) * | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
EP3033342A1 (en) | 2013-08-13 | 2016-06-22 | Grünenthal GmbH | Annelated pyrroles and their use as crac inhibitors |
WO2015054283A1 (en) | 2013-10-08 | 2015-04-16 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2015090580A1 (en) | 2013-12-18 | 2015-06-25 | Grünenthal GmbH | Pyrazolyl-based carboxamides useful as calcium release activated calcium channel (icrac) inhibitors |
WO2015197188A1 (en) | 2014-06-24 | 2015-12-30 | Grünenthal GmbH | Pyrazolyl-based carboxamides as crac inhibitors |
JP6764866B2 (ja) | 2015-01-13 | 2020-10-07 | ビブレオン バイオサイエンシーズ,エルエルシー | Ca2+放出活性化Ca2+(CRAC)チャネルのモジュレーターおよびその薬学的使用 |
ITUA20164199A1 (it) | 2016-06-08 | 2017-12-08 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Modulatori di soce compisizioni e relativi usi |
AU2018211966B2 (en) | 2017-01-26 | 2024-03-07 | Calcimedica, Inc. | CRAC channel inhibitor compositions |
WO2019082124A1 (en) * | 2017-10-26 | 2019-05-02 | Rhizen Pharmaceuticals Sa | COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA |
-
2019
- 2019-09-13 BR BR112021004893-6A patent/BR112021004893A2/pt not_active Application Discontinuation
- 2019-09-13 CA CA3112907A patent/CA3112907A1/en active Pending
- 2019-09-13 KR KR1020217009564A patent/KR20210062023A/ko unknown
- 2019-09-13 JP JP2021539683A patent/JP2022508468A/ja active Pending
- 2019-09-13 EA EA202190556A patent/EA202190556A1/ru unknown
- 2019-09-13 WO PCT/IB2019/057746 patent/WO2020053834A1/en unknown
- 2019-09-13 SG SG11202102491RA patent/SG11202102491RA/en unknown
- 2019-09-13 CN CN201980065612.XA patent/CN113557020A/zh active Pending
- 2019-09-13 EP EP19787438.1A patent/EP3849552A1/en not_active Withdrawn
- 2019-09-13 AU AU2019340601A patent/AU2019340601A1/en not_active Abandoned
- 2019-09-13 US US17/250,864 patent/US20220040162A1/en active Pending
- 2019-09-13 MX MX2021003094A patent/MX2021003094A/es unknown
-
2021
- 2021-03-09 IL IL281342A patent/IL281342A/en unknown
- 2021-03-12 CL CL2021000616A patent/CL2021000616A1/es unknown
- 2021-03-30 CO CONC2021/0004013A patent/CO2021004013A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3112907A1 (en) | 2020-03-19 |
BR112021004893A2 (pt) | 2021-06-01 |
US20220040162A1 (en) | 2022-02-10 |
CL2021000616A1 (es) | 2021-10-15 |
AU2019340601A1 (en) | 2021-05-13 |
WO2020053834A1 (en) | 2020-03-19 |
IL281342A (en) | 2021-04-29 |
CO2021004013A2 (es) | 2021-07-19 |
JP2022508468A (ja) | 2022-01-19 |
CN113557020A (zh) | 2021-10-26 |
MX2021003094A (es) | 2021-05-12 |
EA202190556A1 (ru) | 2021-08-24 |
KR20210062023A (ko) | 2021-05-28 |
EP3849552A1 (en) | 2021-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277434A (en) | SHP2 phosphatase inhibitors and methods of using them | |
IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
EP3723770A4 (en) | COMPOSITIONS WITH CHEMOTHERAPEUTICS AND CHECKPOINT INHIBITORS AND METHOD OF USE | |
EP3572400C0 (en) | EZH2 INHIBITOR AND ITS USE | |
IL287751A (en) | kcnt1 inhibitors and methods of use | |
IL287768A (en) | kcnt1 inhibitors and methods of use | |
IL287973A (en) | acss2 inhibitors and methods of their use | |
IL274504A (en) | 2ACSS inhibitors and methods of their use | |
EP3595658A4 (en) | FORMS AND COMPOSITIONS OF A MK2 INHIBITOR | |
EP3768267A4 (en) | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | |
IL280414A (en) | Bismuth-thiol preparations and methods of use | |
IL276135A (en) | Preparations and methods of use | |
IL282350A (en) | Bernani-RGMC inhibitors and their use | |
EP3846808A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
IL282688A (en) | A cyclodextrin-based formulation of a BCL-2 inhibitor | |
EP3906028A4 (en) | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | |
EP3906233A4 (en) | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | |
IL279276A (en) | ERK inhibitor and use thereof | |
EP4071155A4 (en) | THIAZOLOLACTAM COMPOUND USED AS ERK INHIBITOR AND USE THEREOF | |
IL286485A (en) | pi4-kinase inhibitors and methods of using them | |
IL281342A (en) | Preparations include a CRAC inhibitor and a corticosteroid and methods of using them | |
EP3793552C0 (en) | ABHD12 INHIBITORS AND METHODS OF MANUFACTURE AND USE THEREOF | |
EP3717475A4 (en) | KINASEINHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | |
EP4077332A4 (en) | LIN28 INHIBITORS AND THEIR METHODS OF USE | |
IL283106A (en) | erk inhibitors and their uses |